Letter to the Editor
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Aug 27, 2022; 14(8): 862-866
Published online Aug 27, 2022. doi: 10.4240/wjgs.v14.i8.862
Sirolimus vs tacrolimus: Which one is the best therapeutic option for patients undergoing liver transplantation for hepatocellular carcinoma?
Faiza Ahmed, Faiza Zakaria, Godsgift Enebong Nya, Mohamad Mouchli
Faiza Ahmed, Division of Clinical and Translational Research, Larkin Community Hospital-Larkin Healthcare Systems, South Miami, FL 33143, United States
Faiza Zakaria, Department of Internal Medicine, Dow Medical College, Karachi 75400, Pakistan
Godsgift Enebong Nya, Department of Gastroenterology, John Hopkins Hospital, Baltimore, MD 21218, United States
Mohamad Mouchli, Department of Gastroenterology, Cleveland Clinic, Cleveland, OH 44195, United States
Author contributions: All authors contributed to the conception, writing, and review of the article and approved the submitted version.
Conflict-of-interest statement: The authors declare no conflict of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Faiza Ahmed, BSc, MD, MSc, Instructor, Research Scientist, Senior Researcher, Division of Clinical and Translational Research, Larkin Community Hospital-Larkin Healthcare Systems, 7031 SW 62nd Ave, South Miami, FL 33143, United States. dr.faiza.ahmed11@gmail.com
Received: January 31, 2022
Peer-review started: January 31, 2022
First decision: June 19, 2022
Revised: July 2, 2022
Accepted: July 20, 2022
Article in press: July 20, 2022
Published online: August 27, 2022
Processing time: 204 Days and 13 Hours
Core Tip

Core Tip: Post-transplant rejection holds significance in the long-term survival of patients with hepatocellular carcinoma (HCC) receiving a liver transplant (LT). The role of the mammalian target of rapamycin inhibitor (mTOR inhibitors) in preventing HCC recurrence after LT is still under debate. The major goal of this letter is to summarize the most relevant existing data on sirolimus, an mTOR inhibitor, and tacrolimus, a calcineurin inhibitor, therapy involvement in the progression of such patients.